伏诺拉生二联方案治疗幽门螺杆菌再感染疗效  

Efficacy of Vonoprazan Dual Therapy in Treating Recurrent

作　　者：严晓飞 宋建国 袁丽 YAN Xiaofei;SONG Jianguo;YU Li(Department of Gastroenterology,Donghai County People's Hospital,Lianyungang,Jiangsu,222300,China;Department of Gastroenterology,The Second Poverty Alleviation Hospital of Xinjiang Uygur Autonomous Region,Xin Jiang,2830000,China;Department of Outpatient Western Medicine Pharmacy,Donghai County Traditional Chinese Medicine Hospital,Lianyungang,Jiangsu 222300,China)

机构地区：[1]江苏省东海县人民医院消化内科,江苏连云港222300 [2]新疆维吾尔自治区第二济困医院脾胃科,乌鲁木齐830000 [3]江苏省东海县中医院门诊西药房,江苏连云港222300

出　　处：《新疆医学》2025年第3期270-272,共3页Xinjiang Medical Journal

基　　金：新疆维吾尔自治区自然科学基金(项目编号:2022D01A307)。

摘　　要：目的探究伏诺拉生二联方案治疗初治失败的幽门螺旋杆菌感染的临床效果。方法随机遴选2022年12月~2023年8月在本院初治失败的幽门螺旋杆菌感染患者80例作为研究对象,依据治疗方法完成组别划分,对照组40例患者给予阿莫西林+呋喃唑酮+枸橼酸铋钾+雷贝拉唑四联方案进行治疗;而观察组40例患者则给予阿莫西林+伏诺拉生二联方案进行治疗。对比2组:(1)药物不良反应情况;(2)治疗结束1月后根除率;(3)治疗结束3月后复发情况。结果对比2组患者药物不良反应发生率,可以看出观察组的不良反应发生率低于对照组(P<0.05);治疗结束1个月后,观察组患者Hp根除率明显更高,与对照组相比较存在统计学意义(P<0.05)。3个月后,两组Hp根除成功患者复查C14呼气试验结果均阴性。结论针对初治失败的幽门螺旋杆菌感染患者展开伏诺拉生联合阿莫西林进行治疗,Hp根除率高,安全有效,值得推广。Objective To explore the clinical efficacy of the dual regimen of vorolaxen in the treatment of Helicobacter pylori infection with initial treatment failure.Method Patients with Helicobacter pylori infection who failed initial treatment in our hospital from December 2022 to August 2023 were randomly selected as the research subjects.80 cases were selected from them and divided into groups according to the treatment method.The control group of 40 patients was treated with amoxicillin and furazolidone;And 40 patients in the observation group were treated with amoxicillin and vorolaxen in the observation group.Comparison of two groups:①Adverse drug reactions;②Eradication rate after 1 month;③Recurrence after 3 months.Result Comparing the incidence of adverse drug reactions between the two groups of patients,it can be seen that the incidence of adverse reactions in the observation group is lower than that in the control group(P<0.05);After one month,the Hp eradication rate in the observation group was significantly higher than that in the control group,with statistical significance(P<0.05).After 3 months,there was no recurrence in the both group.Conclusion For patients with Helicobacter pylori infection who have failed initial treatment,the combination of vorolaxen and amoxicillin treatment can not only improve the eradication rate of Hp,but also reduce disease recurrence,and is safe and effective,which is worth promoting.

关 键 词：伏诺拉生 二联方案 初治失败 幽门螺旋杆菌感染 临床疗效 

分 类 号：R573.6[医药卫生—消化系统]